Type of respondents	Number of respondents	Estimated number of responses per respondent	Average burden hours per response	Annual burden hours requested
Initial Applicants	1900	1	10.35	19,665.00
Advisors/Supervisors	1750	1	.5	875.00
Recommenders	5700	1	.33	1881.00
Financial Institutions	300	1	1.25	375.00
Subtotal	9650			22,796.00
Intramural LRPs:				
Renewal Applicants	60	1	7.42	445.20
Advisors/Supervisors	60	1	1.33	79.80
Subtotal	120			525.00
Extramural LRPs:				
Renewal Applicants	1225	1	8.58	10,510.50
Advisors/Supervisors	925	1	1.00	925.00
Recommenders	3675	1	.33	1212.75
Subtotal	5825			12,648.25
Total	15,755			36,329.75

The annualized cost to respondents is estimated at $1,298,341. The annualized cost to the Federal Government for administering the Loan Repayment Programs is expected to be $1,794,667.48. This cost includes administrative support by the Division of Loan Repayment and $440,039 for the continuing development and maintenance of the LRP Management Information System/Online Application System (MIS/OAS).

Request For Comments: Written comments and/or suggestions from the public and affected agencies should address one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

Direct Comments to OMB: Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, *OIRA_submission@omb.eop.gov* or by fax to 202–395–6974, Attention: Desk Officer for NIH. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Suman King, PhD., Director, Division of Loan Repayment, National Institutes of Health, 6011 Executive Blvd., Room 206 (MSC 7650), Bethesda, Maryland 20892–7650. Dr. King may be contacted via e-mail at *SKing1@od.nih.gov* or by calling 301–594–3234.

Comments Due Date: Comments regarding this information collection are best assured of having their full effect if received within 30 days of the date of this publication.

Dated: March 27, 2008.

Raynard S. Kington,

Deputy Director, NIH.

[FR Doc. E8–6857 Filed 4–2–08; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

HPV Virus-Like Particles for Delivery of Gene-Based Vaccines

Description of Technology: The invention describes methods of eliciting immune responses and treating disease based on novel vaccine compositions and vaccination strategies employing human papilloma virus (HPV) virus-like particles (VLPs), comprising L1 and L2 proteins. These VLPs have the capacity to incorporate up to 8 kb of DNA into the shell and express only the target antigen. These compositions are effective at eliciting an immune response to the transgene product expressed by the DNA when administered at epithelial surfaces including the mucosa (e.g. nasal or respiratory passages or genital tract) or skin in conjunction with disruption of the epithelial layer. It is typically difficult to elicit an immune response in

the genital tract, so this technology overcomes a previous deficiency. Robust B and T cell responses were elicited in mice using the subject technology with representative DNA expressing M/M2 from respiratory syncytial virus (RSV). This technology could be used in a prime-boost vaccination regimen as well to enhance the immune response.

Applications: Vaccines against a number of pathogens, including HPV, HIV, HSV, HCV, and RSV.

Advantages:

Novel, non-invasive vaccine strategy to elicit both systemic and mucosal immunity in typically poorly inductive sites.

Packaging system that can accommodate up to 8 kb of DNA.

No expression of viral genes.

Potential for multivalent vaccine development against heterologous pathogens.

Development Status: Animal (mouse) data available.

Inventors: Barney S. Graham et al. (NIAID) and John T. Schiller et al. (NCI).

Publications:

1. Meeting abstract from the Keystone Symposium on Viral Immunity 2008 can be provided upon request.

2. CB Buck, DV Pastrana, DR Lowy, JT Schiller. Efficient intracellular assembly of papillomaviral vectors. J. Virol. 2004 Jan;78(2):751–757.

Patent Status: U.S. Provisional Application No. 61/022,324 filed 19 Jan 2008 (HHS Reference No. E–077–2008/0–US–01).

Licensing Status: Available for exclusive or non-exclusive licensing.

Licensing Contact: Susan Ano, Ph.D.; 301–435–5515, *anos@mail.nih.gov.*

Collaborative Research Opportunity: The NIAID/OTD is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize HPV Virus-Like Particles for Delivery of Gene-Based Vaccines. Please contact either Cecelia Pazman or Barry Buchbinder at 301–496–2644 for more information.

Avian Influenza Vaccine

Description of Technology: Sustained outbreaks of highly pathogenic avian influenza H5N1 in avian species increase the risk of reassortment and adaptation to humans. The ability to contain its spread in birds would reduce this threat and help maintain the capacity for egg-based vaccine production.

This technology describes DNA vaccines against avian influenza. These vaccines were used to elicit antibodies in animals that were effective against homologous and heterologous H5 challenge studies. One vaccine, a trivalent combination of H5 immunogens, was particularly effective in conferring protection. These vaccines can be delivered intramuscularly or through needle-free delivery mechanism.

Applications: Avian influenza vaccine specifically designed for poultry and other avian species.

Advantages: Protects against homologous and heterologous challenges; Needle-free delivery elicits robust immune response.

Development Status: Animal (mouse and chicken) data available.

Inventors: Gary Nabel, Srinivas Rao, Wing-pui Kong, Zhi-yong Yang, and Chih-jen Wei (VRC/NIAID).

Patent Status:

U.S. Provisional Application No. 61/021,586 filed 16 Jan 2008 (HHS Reference No. E–050–2008/0–US–01).

U.S. Provisional Application No. 61/023,341 filed 24 Jan 2008 (HHS Reference No. E–050–2008/1–US–01).

U.S. Patent No. 7,094,598 issued 22 Aug 2006 (HHS Reference No. E–241–2001/1–US–01) and associated foreign rights (CMV/R vector).

Licensing Status: Available for exclusive or non-exclusive licensing; CMV/R vector is available on a non-exclusive basis only.

Licensing Contact: Susan Ano, Ph.D.; 301–435–5515; *anos@mail.nih.gov.*

Codon Optimized Genes for Subunit Vaccines

Description of Technology: Available for licensing from the NIH are gene constructs that express immunogenic proteins based on viral genes that have been optimized for expression in mammalian cells. Using vaccine vectors expressing respiratory syncytial virus (RSV) proteins from the optimized genes, this technology was shown to result in a potent RSV-specific cellular immune responses with favorable phenotypic patterns. This technology was shown to generate a superior immune (both humoral and cellular) response when utilized as part of a heterologous vector prime-boost regimen. Such optimized genes could be an important component of an effective RSV vaccine. Further, this optimization could have possible application of to other viral genes and their respective vaccines.

Applications: Vaccines; Improved protein expression.

Development Status: Animal (mouse) data available.

Inventors: Barney S. Graham and Teresa R. Johnson (VRC/NIAID).

Patent Status:

U.S. Provisional Application No. 60/872,071 filed 30 Nov 2006 (HHS Reference No. E–326–2006/0–US–01).

PCT Application No. PCT/US2007/024625 filed 30 Nov 2007 (HHS Reference No. E–326–2006/1–PCT–01).

Licensing Status: Available for non-exclusive or exclusive licensing.

Licensing Contact: Susan Ano, Ph.D.; 301–435–5515; *anos@mail.nih.gov.*

Dated: March 25, 2008.

Steven M. Ferguson,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. E8–6893 Filed 4–2–08; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the AIDS Research Advisory Committee, NIAID.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: AIDS Research Advisory Committee, NIAID; AIDS Vaccine Research Subcommittee.

Date: May 30, 2008.

Time: 8:30 a.m. to 5 p.m.

Agenda: To discuss the implication of recent vaccine trial results for future HIV vaccine development.

Place: Betheda North Marriott Hotel and Conference Center, 5701 Marinelli Road, Rockville, MD 20852.

Contact Person: James A. Bradac, PhD, Program Official, Preclinical Research and Development Branch, Division of AIDS, Room 5116, National Institutes of Health/NIAID, 6700B Rockledge Drive, Bethesda, MD 20892–7628, 301–435–3754, *jbradac@mail.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: March 26, 2008.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E8–6711 Filed 4–2–08; 8:45 am]

BILLING CODE 4140–01–M